Sanofi Completes Dosing in Phase 1 Trial of 'Dupixent' Utilizing Alteogen's Technology
Sanofi's 'Dupixent' (ingredient: dupilumab), which utilizes Alteogen's subcutaneous (SC) injection platform technology, has completed dosing for participants in its phase 1 clinical trial.
Exterior view of Alteogen headquarters and research center in Yuseong-gu, Daejeon. Alteogen
View original imageAccording to the clinical information site ClinicalTrials on July 23, Sanofi plans to complete its phase 1 clinical trial of Dupixent, administered in combination with Alteogen's hyaluronidase 'ALT-B4' (ingredient: verahyaluronidase alpha), by September.
This phase 1 trial, which began in June, was conducted on 40 healthy adult participants. The purpose of the trial is to evaluate the pharmacokinetics (PK), safety, and anti-drug antibodies (ADA) following the co-administration of Dupixent and ALT-B4.
Hot Picks Today
"I Ate at Home to Save Money, But My Account Balance Was Still a Shock"
- Suddenly Called Out During Class, Awarded $100,000 as Students Cheer in the Gym
- "Hacker’s Identical IP Detected Across Financial Institutions... Large-Scale Attacks Using AI"
- "After a Dream About Feces, Bought a Lottery Ticket and Won 20,000 Won... Scratched Again and Hit a 2 Billion Won Jackpot"
- "Uncle Will Buy Them All for Wonie"... Men in Their 30s Sweep Up 600,000 'RESCENE Bread'
The ALT-B4 used in this trial is a recombinant human hyaluronidase enzyme developed by Alteogen, enabling the subcutaneous injection of large-volume drugs and facilitating their absorption in the body. Sanofi is utilizing Alteogen's technology to develop a new formulation of Dupixent aimed at improving dosing convenience.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
